Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Solid Tumor 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Biliary Tract Carcinoma 1

Interventions

Nivolumab 7toripalimab 5Injections 5tislelizumab 3pembrolizumab 3spartalizumab 2sintilimab 2osimertinib 2Paclitaxel 2Ipilimumab 2Gemcitabine 2Cisplatin 2Carboplatin 2zimberelimab 1ulocuplumab 1sotorasib 1famitinib 1donafenib 1cemiplimab 1binimetinib 1avelumab 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Taxes 1SHR-1701 1Oxaliplatin 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1LY-2157299 1Immunotherapy, Adoptive 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor × donafenib × Clear all
NCT06239298 2024-06-14

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Recruiting
130 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡